Profile Image

Dr Nikki Verrills

Senior Lecturer

School of Biomedical Sciences and Pharmacy (Medical Biochemistry)

Honing in on her target

Dr Nikki Verrills' research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Nikki Verrills in the laboratory 

As a young undergraduate studying science, Dr Nikki Verrills had intentions of transferring to medicine. Then, she discovered a passion for laboratory research and realised she could effectively fight disease on another front.

"In the end I have achieved the best of both worlds," the biochemist and cancer researcher points out. "I am still in the medical field helping patients by contributing to the development of better treatments but I am also able to pursue my interest in lab work, which I find fascinating."

Verrills has certainly found her niche. Since completing her PhD in 2005 she has worked largely full-time in academic research, collecting a clutch of early career awards, fellowships and major grants in recognition of her groundbreaking research into leukaemia and breast cancer. She studies the molecular pathways of cancer, identifying genes and proteins in cancer cells in order to make comparisons between normal cells and cancer cells. She also analyses differences between cancer cells that respond well to drug treatments and those that do not.

"If scientists can identify proteins that are different in cancerous cells, or in drug-resistant cells, then we can design drugs to target those differences – drugs that will specifically kill cancerous cells but not normal cells," she explains. "That is fundamental cancer research, but most cancer drugs work by turning off a particular protein, or inactivating it. What is novel about our work is that we have targeted a protein that needs to be switched back on."

That protein is phosphatase 2A, or PP2A, which comes from a class of proteins known as 'tumour suppressors'. Normally, they act as a stop signal to inhibit the growth of cancerous cells. In leukaemia cells, however, PP2A is inactive, so the cancer cells continue to proliferate.

In 2007, Verrills worked with collaborators in the United States to prove that the drug FTY720 could effectively switch PP2A on in patients with chronic myeloid leukaemia (CML) – therefore stopping the cancer's spread without affecting the body's healthy cells. This year she was awarded a $360,000 grant from the Cure Cancer Australia Foundation and Cancer Council NSW to apply that research to a different cancer, acute myeloid leukaemia (AML), which has a very poor survival rate.

"There is a real urgency to find new treatments for AML because the vast majority of patients are resistant to chemotherapy and will die of the disease," Verrills asserts. The grant will allow Verrills and her team to test FTY720 and other drugs in different sub-types of AML, and move their work from the laboratory into clinical trials.

"Another focus of our work is establishing exactly how these types of drugs work," she outlines. "We know the end result is that they increase activity of PP2A but we want to advance the knowledge in this field by finding out specifically how they do that. Also, we know from literature that this class of proteins is important in a lot of solid tumours, so it is likely that this research will be applicable to other cancers as well."

Verrills has received ongoing support from high-profile national cancer organisations and has forged collaborations with key research groups in Australia and internationally. She also works closely with colleagues in the University's Centres for Cancer and Chemical Biology and through her links with the Hunter Medical Research Institute (HMRI) has established important working relationships with cancer specialists and haematologists. Her articles are published in internationally prominent journals and she has been recognised with a Voiceless Eureka Prize for Research for her commitment to minimising the use of animals in laboratory work. 

Verrills' doctoral studies into chemotherapy resistance in childhood leukaemia led to a Peter Doherty Postdoctoral Fellowship from the National Health and Medical Research Council in 2006. In the same year she was the inaugural recipient of a Hunter Medical Research Foundation grant for young cancer researchers. She is currently supported by an Early Career Researcher Fellowship with the Cancer Institute of NSW.

Verrills gained exposure during her doctoral studies to cutting-edge scientific techniques used at the Australian Proteomic Analysis Facility, in Sydney, becoming one of the first researchers in the country to use Difference In-Gel Electrophoresis (DIGE). This technique allows simultaneous analysis of proteins in cancerous, non-cancerous and control cells and vastly improves the efficiency and accuracy of testing.

The scientist admits that work/life balance is an elusive concept given her demanding research career, two young daughters and family interest in a vineyard (in which her husband Michael De Iuliis, a fellow scientist, is chief winemaker). But she praises the support of the University of Newcastle, which has allowed her to maintain the momentum of her research while juggling life's other commitments.

"Not only has the University supported me but it has also shown a lot of confidence in me, which is critical for career advancement," Verrills acknowledges. "I have my own research group and I have reached the stage of being an independent researcher much earlier than I probably would have anywhere else."

Visit the Priority Research Centre for Cancer

Visit the Priority Research Centre for Chemical Biology

Visit the HMRI website

Nikki Verrills in the laboratory

Honing in on her target

Dr Nikki Verrills’ research into a key signalling switch in cancer cells could provide an important breakthrough in treatment.

Read more

Career Summary

Biography

Dr Verrills research interests centre on understanding the signalling pathways involved in cancer development, progression and resistance to chemotherapy induced cell death. Her research involves cell biology and biochemistry, translation into clinically relevant mouse models of disease, and analysis of primary patient samples. During her PhD studies Dr Verrills used powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, to discover novel protein alterations that confer chemotherapy resistance in childhood leukaemia.

In postdoctoral studies Dr Verrills further applied her proteomics skills to the investigation of respiratory disease, and has identified clinical biomarkers for asthma and chronic obstructive pulmonary disease. These proteins are now targets for patent applications and ongoing investigations into the development of diagnostics and improved therapies. Her postdoctoral studies in respiratory disease led to an interest in signalling pathways, with particular interest in the multifunctional protein phosphatase, PP2A. This led her to establish a research group investigating the role of protein phosphatase 2A (PP2A) in cellular functions. Her group has discovered novel roles for PP2A in cellular function and disease, including myeloid leukaemias, melanoma and asthma, and demonstrated that PP2A activation is a potential strategy for improved therapies (e.g. senior author papers in Cancer Research and Cell Signalling, and co-authored papers in Nature Medicine, Journal of Clinical Investigation; J Biol Chem; BBA; Cell Death & Diff). She has developed a unique panel of PP2A molecular reagents (shRNA, overexpression constructs, antibodies, pharmacological activators/inhibitors), and established strategic collaborations which has enabled her to expand her investigations of PP2A into the study of breast cancer.

Her PhD was awarded from Macquarie University in 2005, for which she received a Vice-Chancellor’s Commendation for Excellence in Research. In 2006 Dr Verrills received a highly competitive NHMRC Peter Doherty Postdoctoral Fellowship. Through this fellowship she also received a scholarship to the Australian Academy of Science “Science at the Shine Dome” meeting. In 2006 she also became the inaugural recipient of the Hunter Medical Research Institute (HMRI) Competitive Research Fund for Early Career Researchers in Cancer. In 2010 Dr Verrills was appointed to an ongoing academic position (Lecturer) at the University of Newcastle, however in 2011 she was awarded a Cancer Institute NSW Early Career Research Development Award, and after deferring this for a year for maternity leave, she took up this fellowship in Dec 2011.

Research outputs: Dr Verrills has 28 research publications, with 13 as first or senior author, appearing in journals of good to high impact in the field (average IF 6.4) and are well cited (>800 to date; average 59 cites/yr; h-index 14). The importance of her work has also been featured in editorial articles (Fojo, T (2006) J Natl Cancer Inst 98: 1363 and Ojima and Ferlini (2003) Chem Biol 10: 583).

Funding: Since 2006 Dr Verrills has attracted >$3M in competitive research grant/fellowship funding, from the NHMRC, Cancer Council NSW, Anthony Rothe Foundation, Ramaciotti Foundation, Cancer Institute NSW, Cure Cancer Australia Foundation, and the Hunter Medical Research Institute (HMRI). She has also attracted infrastructure funding from the ARC, ACRF, Ramaciotti Foundation and the Cancer Institute NSW of > $6.4M.

Awards: Dr Verrills research is internationally competitive and recognised through continued publications, presentations at international and national meetings, and international and national awards. These include the 2012 Newcastle Innovations ‘Rising Star Award’; 2010 HUPO Young Guns Award; 2007 Voiceless Eureka Prize; the 2007 Young Tall Poppy Award; the 2007 University of Newcastle Vice Chancellor’s Award for Research Excellence; 2004 Biochemical Journal Young Investigator Award, presented to the best young researcher at the 12th International Conference on Second Messengers and Phosphoproteins, Montreal, Canada; the Merck Sharp Dohm “Best of the Best” Award and the Cure Cancer Australia Foundation Award, both presented at the 2004 Australian Health and Medical Research (ASMR) Congress. In 2003 Dr Verrills was awarded the University of Sydney Medal for Excellence in Medical Research, presented to the best young researcher at the ASMR NSW Conference, and was a finalist in the Cure Cancer Australia Foundation’s Young Researcher of the Year Award.

Service to the discipline: Her expertise in the field of proteomics and cancer biology results in invitations to peer review grant applications (e.g. NHMRC, ARC, Wellcome Trust; AICR; Cure Cancer Australia Foundation), ~20 manuscripts/year for a variety of journals (e.g. Blood, Oncogene, Cancer Research; Molecular Cancer Therapeutics; Proteomics), and ~2 PhD theses/year. In 2012 and 2013 Dr Verrills was a panel member for the NHMRC Cancer Biology & Oncology grant review panel. She has also served on the Leukaemia Foundation PhD and Postdoctoral fellowship review panels. Dr Verrills is a mentor in a University run mentoring program for early career researchers, and has given many lectures to undergraduate, graduate, and school students on careers in medical research.

Invited presentations: In 2012 Dr Verrills was an invited speaker at the International meetings: Phophatases in Disease, Vic; 37th Annual Lorne Proteins Meeting, Vic; Garvan Signalling Meeting, Sydney; Australian Society for Medical Research (ASMR) NSW Branch Scientific Meeting, Sydney. She was also session chair for the ASMR NSW Branch Scientific Meeting and the New Directions in Leukaemia Research, Sunshine Coast. She regularly presents her research to other universities and research institutes. For example, in 2012 she presented at the Lowy Cancer Centre, UNSW, in 2010 at IMVS, Adelaide, and at Pharmaxis in Sydney. In past years she has presented at Macquarie University, The Oncology Research Unit, Westmead, and the Children’s Cancer Institute Australia, Sydney.

Student Supervision: Dr Verrills has been primary supervisor for 3 PhD students to completion, and a further student recently submitted. These students received a number of awards during their studies. She has supervised four Honours students (all received 1st Class).

Conference coordination: Dr Verrills was co-convenor for the international meeting: HMRI Translational Cancer Conference – Pathways to Tailored Therapies, Newcastle, 2008, and was on the organising committee for the 2006 HMRI Conference on Translational Cancer Research and again for the 2013 Conference.

Committees: Dr Verrills is an active member of the Hunter Medical Research Institute Cancer Research Program Steering committee, where she has taken a major role in building up the activities of the program including preparing strategic plans, infrastructure and program funding applications, inviting speakers and establishing an annual research seminar day to foster internal research collaborations. She is also a member of the University of Newcastle’s Australian Biomolecular Research Facility steering committee.

Community engagement: She has a strong commitment to the advancement and promotion of medical research in our society. As part of her community involvement she has disseminated her research through the print, radio, and television media, and has presented her research to the local community as a guest speaker at Rotary and Lions Clubs, and HMRI, Cure Cancer Australia, and Cancer Council NSW charity events. Through the Tall Poppy Campaign she has also presented her research to High School students across NSW, and has established relationships with her local school communities to foster and encourage an interest in studying science.

Current position: In Dec 2011 Dr Verrills returned from maternity leave as a Research Only Academic at the University of Newcastle, working 0.6FTE, funded by a Cancer Institute NSW ECR Development Award.

Research Expertise
Dr Verrills research interests centre on understanding the molecular changes involved in cancer progression and chemotherapy resistance. By using powerful proteomics techniques, including being one of the first in Australia to use difference in-gel electrophoresis (DIGE) technology, she has discovered novel protein alterations that confer chemotherapy resistance in childhood leukaemia. These proteins are now targets for ongoing investigations to develop improved therapies for relapsed leukaemia patients. Dr Verrills is currently investigating the role of the signaling protein, protein phosphatase 2A, in cancer. Using shRNA and overexpression transfection of normal and cancer cell lines, coupled with molecular and biochemical analyses such as PCR, immunoblotting, immunoprecipitation, immunofluorescence, 2D-DIGE and mass spectrometry, she is determining the role of mutant PP2A and specific PP2A subunits in the development of leukaemia and breast cancer.

Teaching Expertise
Dr Verrills is a strong supporter of fostering research students. She has supervised two Honours student (both received 1st Class), and is currently supervising one Honours and three PhD students. Dr Verrills is a fulltime research academic, however she does guest lecture for 2nd and 3rd year BBiomed Sci courses in Proteomics, Bioinformatics, Cancer, and Drug Resistance.

Administrative Expertise
Dr Verrills undetakes many administrative tasks, including managing the budgets for her grants. Some duties include obtaining product quotes, ordering, safety and ethics applications, co-ordinating multi investigator grant applications, and organising research seminar series and workshops.



Qualifications

  • Bachelor of Science (Honours), Macquarie University

Keywords

  • Breast Cancer
  • Cancer
  • Chemotherapy resistance
  • Drug resistance
  • Leukaemia
  • Protein phosphatase 2A
  • Proteomics
  • Signal transduction

Fields of Research

CodeDescriptionPercentage
060199Biochemistry and Cell Biology not elsewhere classified75
111599Pharmacology and Pharmaceutical Sciences not elsewhere classified15
111299Oncology and Carcinogenesis not elsewhere classified10

Professional Experience

UON Appointment

DatesTitleOrganisation / Department
1/01/2015 - 30/11/2016Senior LecturerUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia

Academic appointment

DatesTitleOrganisation / Department
21/05/2015 - 21/06/2015Postdoctoral ScientistUniversity of Newcastle
Australia
1/01/2012 - 31/12/2013Membership - NHMRC Grant Review PanelNHMRC Grant Review Panel
Australia
1/01/2011 - FellowUniversity of Newcastle
School of Biomedical Sciences and Pharmacy
Australia
1/01/2011 - Cancer Institute NSW ECD Research FellowFamily Action Centre University of Newcastle
Australia
1/01/2006 - 1/07/2010Peter Doherty Biomedical Fellow
NHMRC - Early Career Fellowships (Formerly Postdoctoral Training Fellowships)
National Health & Medical Research Council
1/01/2001 - Membership - Australian Society for Medical ResearchAustralian Society for Medical Research (ASMR)
Australia
1/01/1999 - 2/01/2001Research AssistantMacquarie University
Australia

Membership

DatesTitleOrganisation / Department
Organising Committee Member - HMRI Conference on Translational Cancer ResearchHunter Medical Research Institute (HMRI)
Australia
Committee Member - HMRI Cancer Research Group Steering CommitteeHunter Medical Research Institute (HMRI)
Australia
Member - American Association of Cancer ResearchAmerican Association of Cancer Research
United States

Awards

Honours

YearAward
1998Bill Cantwell prize for Excellence in Biology
Macquarie University

Recipient

YearAward
2003Australian Proteome Analysis Facility Scholarship 2001-2003
Australian Proteome Analysis Facility
2003Australian Postgraduate Award 2001-2003
Macquarie University

Recognition

YearAward
20052005 - Doctor of Philosophy, Vice Chancellor Commendation.
Macquarie University
20032003 - Cure Cancer Australia Foundation's Young Researcher of the Year Award - Finalist.
Cure Cancer Australia Foundation

Research Award

YearAward
2004Biochemical Journal Young Investigator Award - 12th International Conference on Second Messengers and Phosphoproteins
The Biochemical Journal
20042004 - Merck Sharp Dohm 'Best of the Best' Award - Australian Health and Medical Research Congress
Australian Society of Medical Research
20042004 - Cure Cancer Australia Foundation Award
Cure Cancer Australia Foundation
20032003 - University of Sydney Medal for Excellence in Medical Research
Australian Society of Medical Research

Invitations

Participant

YearTitle / Rationale
2003Protemics for cancer research
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003Proteome analyses reveals novel mechanisms of resistance to anticancer agents.
Organisation: Oncology Research Unit, Childrens Hospital, Westmead.
2003Amersham Biosciences Technical Seminar Series. Brisbane; Adelaide; Melbourne; Sydney.
Organisation: GE Biosciences Description: Amersham Biosciences, now part of GE Healthcare, is a world leader in proteomics technology. I was invited as an expert presenter on the use of state of the art proteomic technology, 2D difference gel electrophoresis, and how this technology can be applied in biomedical research.
2002New technologies meets functional proteomics.
Organisation: ComBio 2002 Description: This was a special session at the ComBio meeting convened bythe Australian Proteomics Society and was an invited speaker.
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

YearCitationAltmetricsLink
2011Smith AM, Roberts KG, Verrills NM, 'Ser/Thr phosphatases: The new frontier for myeloid leukemia therapy?', Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Intech, Croatia 123-148 (2011) [B1]

Journal article (31 outputs)

YearCitationAltmetricsLink
2014Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV, Cairns MJ, 'Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons.', Nucleic Acids Research, 42 9195-9208 (2014) [C1]
DOI10.1093/nar/gku594Author URL
CitationsScopus - 4Web of Science - 3
Co-authorsMinjie Lin, Matt Dun, Christopher Dayas, Murray Cairns
2014Hatchwell L, Girkin J, Morten M, Collison A, Mattes J, Foster PS, et al., 'Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease¿by modulating protein phosphatase 2A', Journal of Allergy and Clinical Immunology, (2014) [C1]

Background: ß-Agonists are used for relief and control of asthma symptoms by reversing bronchoconstriction. They might also have anti-inflammatory properties, but the underpinning mechanisms remain poorly understood. Recently, a direct interaction between formoterol and protein phosphatase 2A (PP2A) has been described in¿vitro. Objective: We sought to elucidate the molecular mechanisms by which ß-agonists exert anti-inflammatory effects in allergen-driven and rhinovirus 1B-exacerbated allergic airways disease (AAD). Methods: Mice were sensitized and then challenged with house dust mite to induce AAD while receiving treatment with salmeterol, formoterol, or salbutamol. Mice were also infected with rhinovirus 1B to exacerbate lung inflammation and therapeutically administered salmeterol, dexamethasone, or the PP2A-activating drug (S)-2-amino-4-(4-[heptyloxy]phenyl)-2-methylbutan-1-ol (AAL[S]). Results: Systemic or intranasal administration of salmeterol protected against the development of allergen- and rhinovirus-induced airway hyperreactivity and decreased eosinophil recruitment to the lungs as effectively as dexamethasone. Formoterol and salbutamol also showed anti-inflammatory properties. Salmeterol, but not dexamethasone, increased PP2A activity, which reduced CCL11, CCL20, and CXCL2 expression and reduced levels of phosphorylated extracellular signal-regulated kinase 1 and active nuclear factor ¿B subunits in the lungs. The anti-inflammatory effect of salmeterol was blocked by targeting the catalytic subunit of PP2A with small RNA interference. Conversely, increasing PP2A activity with AAL(S) abolished rhinovirus-induced airway hyperreactivity, eosinophil influx, and CCL11, CCL20, and CXCL2 expression. Salmeterol also directly activated immunoprecipitated PP2A in¿vitro isolated from human airway epithelial cells. Conclusions: Salmeterol exerts anti-inflammatory effects by increasing PP2A activity in AAD and rhinovirus-induced lung inflammation, which might potentially account for some of its clinical benefits. © 2013 American Academy of Allergy, Asthma & Immunology.

DOI10.1016/j.jaci.2013.11.014
CitationsScopus - 5Web of Science - 4
Co-authorsPaul Foster, Matt Dun, Joerg Mattes
2014Hoffman A, Carpenter H, Kahl R, Watt LF, Dickson PW, Rostas JAP, et al., 'Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition', Cellular Signalling, 26 748-756 (2014) [C1]

Calcium/calmodulin-stimulated protein kinase II (CaMKII) is a multi-functional serine/threonine protein kinase that controls a range of cellular functions, including proliferation. The biological properties of CaMKII are regulated by multi-site phosphorylation and targeting via interactions with specific proteins. To investigate the role specific CaMKII phosphorylation sites play in controlling cell proliferation and cell cycle progression, we examined phosphorylation of CaMKII at two sites (T253 and T286) at various stages of the cell cycle, and also examined the effects of overexpression of wild-type (WT), T286D phosphomimic, T253D phosphomimic and T253V phosphonull forms of CaMKIIa in MDA-MB-231 breast cancer and SHSY5Y neuroblastoma cells on cellular proliferation and cell cycle progression. We demonstrate herein that whilst there is no change in total CaMKII expression or T286 phosphorylation throughout the cell cycle, a marked dephosphorylation of CaMKII at T253 occurs during the G2 and/or M phases. Additionally, we show by molecular inhibition, as well as pharmacological activation, that protein phosphatase 2A (PP2A) is the phosphatase responsible for this dephosphorylation. Furthermore, we show that inducible overexpression of WT, T286D and T253V forms of CaMKIIa in MDA-MB-231 and SHSY5Y cells increases cellular proliferation, with no alteration in cell cycle profiles. By contrast, overexpression of a T253D phosphomimic form of CaMKIIa significantly decreases proliferation, and cells accumulate in mitosis, specifically in metaphase. Taken together, these results strongly suggest that the dephosphorylation of CaMKII at T253 is involved in controlling the cell cycle, specifically the metaphase-anaphase transition. © 2014 Elsevier Inc.

DOI10.1016/j.cellsig.2013.12.015
CitationsScopus - 2Web of Science - 1
Co-authorsPhil Dickson, Kathryn Skelding, John Rostas
2013Collison AM, Hatchwell LM, Verrills NM, Wark PA, Pereira De Siqueira AL, Tooze MK, et al., 'The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity', Nature Medicine, 19 232-237 (2013) [C1]
CitationsScopus - 32Web of Science - 27
Co-authorsJoerg Mattes, Peter Wark, Paul Foster
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Progression through mitosis can be controlled by dephosphorylation of CaMKII at T253', JOURNAL OF NEUROCHEMISTRY, 123 31-31 (2012) [E3]
Author URL
Co-authorsKathryn Skelding, John Rostas, Phil Dickson
2012Bradbury P, Mahmassani M, Zhong J, Turner K, Paul A, Verrills NM, O'Neill GM, 'PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9', Biochimica Et Biophysica Acta-Molecular Cell Research, 1823 290-297 (2012) [C1]
CitationsScopus - 8Web of Science - 6
2012Tay KH, Jin L, Tseng HY, Jiang CC, Ye Y, Thorne RF, et al., 'Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress', Cell Death and Disease, 3 e337 (2012) [C1]
CitationsScopus - 15Web of Science - 15
Co-authorsXu Zhang, Rick Thorne
2011Skelding KA, Rostas JA, Verrills NM, 'Controlling the cell cycle: The role of calcium/calmodulin-stimulated protein kinases I and II', Cell Cycle, 10 631-639 (2011) [C1]
DOI10.4161/cc.10.4.14798
CitationsScopus - 26Web of Science - 28
Co-authorsJohn Rostas, Kathryn Skelding
2011Roberts KG, McDougall FK, Verrills NM, 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers - Response', Cancer Research, 71 2404-2404 (2011) [C3]
DOI10.1158/0008-5472.can-10-4297
2011Chang H-Y, Jennings PC, Stewart JL, Verrills NM, Jones KT, 'Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720', Journal of Biological Chemistry, 286 14705-14712 (2011) [C1]
DOI10.1074/jbc.M110.193227
CitationsScopus - 18Web of Science - 18
Co-authorsKeith Jones
2011Verrills NM, Irwin JA, He XY, Wood LG, Powell H, Simpson JL, et al., 'Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease', American Journal of Respiratory and Critical Care Medicine, 183 1633-1643 (2011) [C1]
DOI10.1164/rccm.201010-1623OC
CitationsScopus - 36Web of Science - 34
Co-authorsAlistair Sim, Jodie Simpson, Peter Gibson, Lisa Wood, Vanessa Mcdonald
2010Roberts KG, Smith AM, McDougall FK, Carpenter HC, Horan MP, Neviani P, et al., 'Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers', Cancer Research, 70 5438-5447 (2010) [C1]
DOI10.1158/0008-5472.CAN-09-2544
CitationsScopus - 56Web of Science - 52
Co-authorsLeonie Ashman, Alistair Sim
2010Kranias G, Watt L, Carpenter HC, Holst J, Ludowyke R, Strack S, et al., 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', Cellular Signalling, 22 1882-1890 (2010) [C1]
DOI10.1016/j.cellsig.2010.07.017
CitationsScopus - 5Web of Science - 5
Co-authorsAlistair Sim
2010Skelding KA, Suzuki T, Gordon SL, Xue J, Verrills NM, Dickson PW, Rostas JA, 'Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function', Cellular Signalling, 22 759-769 (2010) [C1]
DOI10.1016/j.cellsig.2009.12.011
CitationsScopus - 9Web of Science - 9
Co-authorsJohn Rostas, Phil Dickson, Kathryn Skelding
2008Ong V, Liem NLM, Schmid MA, Verrills NM, Papa RA, Marshall GM, et al., 'A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts', JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 324 434-442 (2008) [C1]
DOI10.1124/jpet.107.128926Author URL
CitationsScopus - 12Web of Science - 12
2007Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW, et al., 'FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia', Journal of Clinical Investigation, 117 2408-2421 (2007) [C1]
DOI10.1172/jci31095
CitationsScopus - 183Web of Science - 180
2006Verrills NM, Po'Uha ST, Liu MLM, Liaw TYE, Larsen MR, Ivery MT, et al., 'Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia', Journal of the National Cancer Institute, 98 1363-1374 (2006) [C1]
DOI10.1093/jnci/djj372
CitationsScopus - 44Web of Science - 40
2006Verrills NM, 'Clinical proteomics: present and future prospects', Clinical Biochemist Reviews, 27 99-116 (2006) [C2]
2006Sim AT, Ludowyke RI, Verrills NM, 'Mast cell function: Regulation of degranulation by serine/threonine phosphatases', Pharmacology & Therapeutics, 112 425-439 (2006) [C1]
DOI10.1016/j.pharmthera.2006.04.011
CitationsScopus - 17Web of Science - 16
Co-authorsAlistair Sim
2006Verrills NM, Liem NL, Liaw TYE, Hood BD, Lock RB, Kavallaris M, 'Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia - an in vivo study', Proteomics, 6 1681-1694 (2006) [C1]
DOI10.1002/pmic.200500417
CitationsScopus - 61Web of Science - 57
2005Kavallaris M, Verrills NM, 'Improving the targeting of tubulin-binding agents: lessons from drug resistance studies', Current Pharmaceutical Design, 11 1719-1733 (2005) [C1]
DOI10.2174/1381612053764706
CitationsScopus - 43Web of Science - 43
2005Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O''Neil GM, et al., 'Tissue-specific tropomyosin isoform composition', Journal of Histochemistry and Cytochemistry: imaging the spectrum of cell biology, 53 557-570 (2005) [C1]
DOI10.1369/jhc.4A6505.2005
CitationsScopus - 64Web of Science - 62
2004Don S, Verrills NM, Liaw TY, Liu ML, Norris MD, Haber M, Kavallaris M, 'Neuronal-associated microtubule proteins class III ß-tubulin ad MAP2c in neuroblastoma: Role in resistance to microtubule-targeted drugs', Molecular Cancer Therapeutics, 3 1137-1146 (2004) [C1]
CitationsScopus - 35Web of Science - 32
2003Verrills NM, Kavallaris M, 'Drug resistance mechanisms in cancer cells: A proteomics perspective', Current Opinion in Molecular Therapeutics, 5 258-265 (2003) [C1]
CitationsScopus - 20Web of Science - 20
2003Mackintosh JA, Choi HY, Bae SH, Veal DA, Bell PJ, Ferrari BC, et al., 'A fluorescent natural product for ultra sensitive detection of proteins in one-dimensional and two-dimensional gel electrophoresis', Proteomics, 3 2273-2288 (2003) [C1]
DOI10.1002/pmic.200300578
CitationsScopus - 95Web of Science - 89
2003Verrills NM, Walsh BJ, Cobon GS, Hains PG, Kavallaris M, 'Proteome analysis of Vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations', Journal of Biological Chemistry, 278 4508-4509 (2003) [C1]
DOI10.1074/jbc.M303378200
CitationsScopus - 59Web of Science - 54
2003Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al., 'Microtubule alterations and mutations induced by desoxyepothilone B: Implications for drug-target interactions', Chemistry and Biology, 10 597-607 (2003) [C1]
DOI10.1016/S1074-5521(03)00141-8
CitationsScopus - 90Web of Science - 85
2001Kavallaris M, Verrills NM, Hill BT, 'Anticancer therapy with novel tubulin-interacting drugs', DRUG RESISTANCE UPDATES 4 (6): 392-401 DEC 2001, 392-401 (2001) [C1]
CitationsScopus - 88Web of Science - 78
2000Verrills NM, Harry JH, Walsh BJ, Hains PG, Robinson ES, 'Cross-matching marsupial proteins with eutherian mammal databases: Proteome analysis of cells from UV-induced skin tumours of an opossum (Monodelphis domestica)', ELECTROPHORESIS 21 (17): 3810-3822 NOV 2000, 3810-3822 (2000) [C1]
CitationsScopus - 12Web of Science - 13
2000Cordwell SJ, Nouwens AS, Verrills NM, Basseal DJ, Walsh BJ, 'Subproteomics based upon protein cellular location and relative solubilities in conjunction with composite two-dimensional electrophoresis gels', ELECTROPHORESIS 21 (6): 1094-1103 APR 2000, 1094-1103 (2000) [C1]
CitationsScopus - 108Web of Science - 100
1999Cordwell SJ, Nouwens AS, Verrills NM, McPherson JC, Hains PG, Van Dyk DD, Walsh BJ, 'The microbial proteome database - an automated laboratory catalogue for monitoring protein expression in bacteria', ELECTROPHORESIS 20 (18): 3580-3588 DEC 1999, 3580-3588 (1999) [C1]
CitationsScopus - 16Web of Science - 17
Show 28 more journal articles

Conference (25 outputs)

YearCitationAltmetricsLink
2014Delforce SJ, Pringle KG, Wang Y, Verrills NM, Scott RJ, Lumbers ER, 'THE FUNCTIONAL ROLE OF THE ENDOMETRIAL RENIN ANGIOTENSIN SYSTEM IN ENDOMETRIAL CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsRodney Scott, Kirsty Pringle
2014Yoon E-J, Chi MN, Enjeti AK, Verrills NM, Skelding KA, 'CHARACTERISING A NEW TARGET FOR THE TREATMENT OF ACUTE LEUKAEMIAS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsKathryn Skelding
2014Dun MD, Kahl RGS, Flanagan H, Cairns MMJ, Smith ND, Enjeti AK, et al., 'IDENTIFICATION OF ONCOGENIC SIGNALLING PATHWAYS IN ACUTE MYELOID LEUKAEMIA (AML) PATIENTS BY PHOSPHOPROTEOMICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsMatt Dun, Murray Cairns
2014De Iuliis GN, Verrills NM, Dun MD, 'IN SILICO ANALYSIS OF THE TARGETS OF SMALL-MOLECULE, ANTI-CANCER COMPOUNDS FOR IMPROVED CANCER THERAPEUTICS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Author URL
Co-authorsMatt Dun, Geoffry DeiuliIs
2013Dun MD, Smith AM, Kahl RGS, Smith ND, Khanna A, Don AS, et al., 'Unraveling the mechanism of action: drugs that activate the tumor suppressor 2A.', CANCER RESEARCH, Washington, DC (2013) [E3]
DOI10.1158/1538-7445.AM2013-2038Author URL
Co-authorsMatt Dun
2012Skelding KA, Dickson PW, Verrills NM, Rostas JA, 'Dephosphorylation of CAMKII at T253 controls progression through metaphase', Abstracts. Australian Neuroscience Society 32nd Annual Meeting, Gold Coast, Queensland (2012) [E3]
Co-authorsPhil Dickson, John Rostas, Kathryn Skelding
2011Collison AM, Hatchwell LM, Pereira De Siqueira AL, Don A, Verrills NM, Foster PS, Mattes J, 'The development of house dust mite-induced allergic airways disease is regulated by a novel E3 ubiquitin ligase-dependent deactivation of a protein phosphatase', Respirology, Perth, WA (2011) [E3]
Co-authorsPaul Foster, Joerg Mattes
2011Hatchwell LM, Collison AM, Pereira De Siqueira AL, Foster PS, Verrills NM, Don A, et al., 'A novel E3 ubiquitin ligase links rhinovirus infection to exacerbation of asthma', Respirology, Perth, WA (2011) [E3]
Co-authorsJoerg Mattes, Paul Foster, Peter Wark
2010Irwin J, Verrills NM, He XY, Powell H, Wood LG, Gibson PG, 'Proteomic biomarkers as novel clinical diagnostics for airway disease', Abstract Book. Human Proteome World Congress Sydney 2010, Sydney, NSW (2010) [E3]
Co-authorsPeter Gibson, Lisa Wood
2010Verrills NM, Roberts KG, Smith AM, McDougall FK, Carpenter HC, Neviani P, et al., 'Targeting the tumour suppressor, PP2A, as a novel therapy for acute myeloid leukaemia', Sydney Cancer Conference 2010. Profiling Risk, Personalising Treatment and Predicting Outcomes. Conference Program and Abstract Book, Sydney, NSW (2010) [E3]
Co-authorsAlistair Sim, Leonie Ashman
2010Gilan O, Jastrezebski K, Diesch J, Verrills NM, Hannan RD, Dhillon AS, 'Functional regulation of the Fra-1/AP-1 Transcription factor via interactions with protein phosphatase 2A', OzBio 2010: The Molecules of Life - from Discovery to Biotechnology. Poster Abstracts, Melbourne, Australia (2010) [E3]
2010Skelding KA, Verrills NM, Dickson PW, Rostas JA, 'Regulation of proliferation of neuroblastoma cells by CaMKII', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authorsPhil Dickson, Kathryn Skelding, John Rostas
2010Skelding KA, Xue J, Suzuki T, Verrills NM, Dickson PW, Rostas JA, 'Mechanisms of phosphorylation-sensitive CaMKII targeting', Proceding of the Australian Neuroscience Society, Sydney, NSW (2010) [E3]
Co-authorsPhil Dickson, Kathryn Skelding, John Rostas
2009Kranias G, Cottrell LF, Carpenter HC, Sim AT, Verrills NM, 'Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation', FEBS Journal, Prague, Czech Republic (2009) [E3]
Co-authorsAlistair Sim
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Functional consequences of CaMKII phosphorylation at THR253 in neurons', ANS 2009 Abstracts: Posters, Canberra, ACT (2009) [E3]
Co-authorsKathryn Skelding, John Rostas, Phil Dickson, Alistair Sim
2009Rostas JA, Skelding KA, Liao X, Verrills NM, Dickson PW, 'Regulation of CaMKII by targeting', Proceedings of the 2nd Australia-China Biomedical Research Conference, - (2009) [E3]
Co-authorsPhil Dickson, John Rostas, Kathryn Skelding
2009Skelding KA, Liao X, Verrills NM, Fluechter L, Dickson PW, Rostas JA, 'CaMKII phosphorylation at T253 alters neuronal growth rates and morphology', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI10.1111/j.1471-4159.2009.06238.x
Co-authorsJohn Rostas, Phil Dickson, Kathryn Skelding
2009Rostas JA, Skelding KA, Verrills NM, Suzuki PW, Dickson T, 'CaMKII binding partners vary with cell type and phosphorylation state', Journal of Neurochemistry, Busan, Korea (2009) [E3]
DOI10.1111/j.1471-4159.2009.06238.x
Co-authorsJohn Rostas, Kathryn Skelding
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Identification of CaMKII binding proteins in brain sensitive to CaMKII phosphorylation state', Proceedings of the Australian Neuroscience Society, Hobart, TAS (2008) [E3]
Co-authorsKathryn Skelding, John Rostas, Phil Dickson, Alistair Sim
2008Skelding KA, Verrills NM, Fluechter L, Sim AT, Dickson PW, Rostas JA, 'Development of a novel method for the identification of CaMKII binding proteins', Journal of Neurochemistry, Shanghai, China (2008) [E3]
Co-authorsAlistair Sim, Kathryn Skelding, John Rostas, Phil Dickson
2007Roberts KG, Ashman LK, Sim AT, Verrills NM, 'Regulation of protein phosphatase 2A (PP2A) B subunits by Bcr/Abl: Potential targets for chronic myeloid leukemia', AACR Meeting Abstracts Online (Abstracts of the 98th AACR Annual Meeting), Los Angeles (2007) [E3]
Co-authorsLeonie Ashman, Alistair Sim
2007Roberts KG, Ashman LK, Sim ATR, Verrills NM, 'Altered expression of PP2A regulatory subunits in chronic myelogenous leukemia: Identifying targets for improved therapies', BLOOD, Atlanta, GA (2007)
Author URL
Co-authorsLeonie Ashman
2006Chang MHY, Engelander J, Verrills NM, Tait AS, Kavallaris M, 'Differential proteomic analysis of low-level anti-microtubule resistance in acute lymphoblastic leukaemia (Poster presentation)', 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (European Journal of Cancer Supplements, Vol 4, no. 12), Prague, Czech Republic (2006) [E3]
CitationsWeb of Science - 1
2006Verrills NM, Carpenter HC, Sim AT, 'Disruption of Actin-containing Protein Phosphatase 2A Complexes Regulates Cell Motility in Neuroblastoma Cells', Molecular & Cellular Proteomics, California, USA (2006) [E3]
Co-authorsAlistair Sim
2004Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu M, Yang N, et al., 'Tropomyosin antibodies identify functionally distinct populations of actin filaments', MOLECULAR BIOLOGY OF THE CELL, Washington, DC (2004)
Author URL
Show 22 more conferences
Edit

Grants and Funding

Summary

Number of grants57
Total funding$8,972,679

Click on a grant title below to expand the full details for that specific grant.


20153 grants / $554,778

A novel biomarker for luminal B breast cancer$359,577

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding
SchemeResearch Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1400487
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Investigating the in-vitro efficacy of potential anti-CFIDS compounds in c-kit+ myeloid cells$170,201

Funding body: National CFIDS Foundation Inc.

Funding bodyNational CFIDS Foundation Inc.
Project TeamDoctor Nikki Verrills
SchemeResearch Grant
RoleLead
Funding Start2015
Funding Finish2015
GNoG1401533
Type Of FundingInternational - Competitive
Category3IFA
UONY

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML)$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeResearch Grant
RoleInvestigator
Funding Start2015
Funding Finish2015
GNoG1500757
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

20147 grants / $800,339

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$600,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Matt Dun, Doctor Nikki Verrills, Associate Professor Martin Larsen
SchemeEarly Career Fellowship
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1300952
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia$67,539

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301353
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Targeting a tumour in breast cancer$37,800

Funding body: Pink Frangipani Ball Organising Committee

Funding bodyPink Frangipani Ball Organising Committee
Project TeamDoctor Nikki Verrills
SchemeResearch Project
RoleLead
Funding Start2014
Funding Finish2014
GNoG1400881
Type Of FundingExternal
CategoryEXTE
UONY

Myr-C310: A new treatment for childhood leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301349
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Preclinical testing of a novel therapeutic strategy for breast cancer $25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding
SchemeProject Grant
RoleLead
Funding Start2014
Funding Finish2014
GNoG1301439
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML).$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills
SchemeProject Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301442
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Identification of BAALC as a new target for the treatment of acute myeloid leukaemia $20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeNear Miss Grant
RoleInvestigator
Funding Start2014
Funding Finish2014
GNoG1301404
Type Of FundingInternal
CategoryINTE
UONY

20134 grants / $414,846

Targeting PP2A to improve the therapeutic efficacy of mutant BRAF inhibitors in melanoma$359,250

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamProfessor Xu Dong Zhang, Doctor Nikki Verrills, Doctor Chen Chen Jiang
SchemeResearch Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1200388
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Targeting BAALC as a new treatment for acute myeloid leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills
SchemeProject Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1301348
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Proteomics of Cancer$6,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Matt Dun, Doctor Nikki Verrills, Dr Anoop Enjeti
SchemeProject Grant
RoleInvestigator
Funding Start2013
Funding Finish2013
GNoG1300054
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20128 grants / $747,800

Activating a tumour suppressor for leukaemia therapy$260,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamDoctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
SchemeResearch Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1100512
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Activating a tumour suppressor for leukaemia therapy they receive$100,000

Funding body: Cure Cancer Australia Foundation

Funding bodyCure Cancer Australia Foundation
Project TeamDoctor Nikki Verrills, Dr Anthony Don, Dr Anoop Enjeti, Associate Professor Jonathan Morris
SchemeResearch Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200007
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Microscopic illumination system for advanced fluorescent protein technology$34,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Rick Thorne, Professor Xu Dong Zhang, Conjoint Associate Professor Murray Cairns, Doctor Nikki Verrills, Doctor Charles De Bock, Doctor Jude Weidenhofer, Doctor Severine Roselli, Doctor Kathryn Skelding, Emeritus Professor Leonie Ashman, Professor Hubert Hondermarck
SchemeEquipment Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1100983
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

Role of CaMKII targeting in neuronal susceptibility to excitotoxic cell death$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamEmeritus Professor John Rostas, Doctor Neil Spratt, Associate Professor Phillip Dickson, Doctor Nikki Verrills
SchemeNear Miss Grant
RoleInvestigator
Funding Start2012
Funding Finish2012
GNoG1200673
Type Of FundingInternal
CategoryINTE
UONY

Activating a tumour suppressor for leukaemia therapy$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills
SchemeNear Miss Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200678
Type Of FundingInternal
CategoryINTE
UONY

Regulation of the cell cycle by phosphorylation dependent targeting of CaMKII$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills, Doctor Kathryn Skelding, Emeritus Professor John Rostas, Associate Professor Phillip Dickson, Conjoint Professor Keith Jones
SchemeNear Miss Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200679
Type Of FundingInternal
CategoryINTE
UONY

FASEB Protein Phosphatases, Snowmass, Colorado USA, 15 - 20 July 2012$1,500

Funding body: University of Newcastle - Faculty of Health and Medicine

Funding bodyUniversity of Newcastle - Faculty of Health and Medicine
Project TeamDoctor Nikki Verrills
SchemeTravel Grant
RoleLead
Funding Start2012
Funding Finish2012
GNoG1200803
Type Of FundingInternal
CategoryINTE
UONY

20117 grants / $1,770,009

Molecular characterisation of TRAIL-regulated signal transduction pathways and their role in the development, persistence, and exacerbation of allergic airways disease$615,048

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamProfessor Joerg Mattes, Doctor Nikki Verrills
SchemeProject Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1000314
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Targeting a tumour suppressor, PP2AS for new Leukaemia therapies$600,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Nikki Verrills
SchemeEarly Career Fellowship
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000861
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Chemical Biology$444,961

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Doctor Warwick Belcher, Doctor Ian Grainge, Professor Christopher Grof, Professor Peter Lewis, Professor Eileen McLaughlin, Doctor Shaun Roman, Conjoint Professor Ray Rose, Doctor Jennette Sakoff, Doctor Nikki Verrills
SchemePriority Research Centre
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100052
Type Of FundingInternal
CategoryINTE
UONY

Preclinical testing of PP2A activating compounds for the treatment of childhood acute lymphoblastic leukaemia$40,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Dr Anthony Don
SchemePaediatric Oncology Project Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1001001
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Regulation of Breast Cancer Growth by a Novel Phosphorylation-Dependent Targeting Mechanism$35,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Kathryn Skelding, Doctor Nikki Verrills, Emeritus Professor John Rostas
SchemeBreast Cancer Project Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1001005
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Targeting PP2A as a Novel Therapeutic Strategy for mutant FLT3* Acute Myeloid Leukaemia$25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Doctor Kyu-Tae Kim, Dr Anoop Enjeti
SchemeProject Grant
RoleLead
Funding Start2011
Funding Finish2011
GNoG1000990
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

IMPLEN NanoPhotometer pearl$10,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamConjoint Associate Professor Murray Cairns, Associate Professor Paul Tooney, Professor Alan Brichta, Emeritus Professor John Rostas, Emeritus Professor Patricia Michie, Conjoint Professor Keith Jones, Professor Ulli Schall, Associate Professor Phillip Dickson, Doctor Frederick Walker, Doctor Rick Thorne, Doctor Chris Dayas, Doctor Nikki Verrills, Doctor Janet Holt, Doctor Severine Roselli, Doctor Kathryn Skelding, Doctor Jude Weidenhofer, Associate Professor Liz Milward, Doctor Charles De Bock, Doctor Julie Merriman-Jones, Doctor Jing Qin Wu, Doctor Bing Liu, Mr Dan Johnstone, Ms Belinda Goldie, Doctor Natalie Beveridge
SchemeEquipment Grant
RoleInvestigator
Funding Start2011
Funding Finish2011
GNoG1100030
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

20104 grants / $839,000

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$500,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamProfessor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG0190402
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

An Integrated LC-MS-NMR facility for Applications in Proteomics and Organic Chemistry$280,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Adam McCluskey, Laureate Professor John Aitken, Professor Paul Dastoor, Professor Phillip Robinson, Professor Eileen McLaughlin, Emeritus Professor Geoffrey Lawrance, Professor Marcel Maeder, Professor Hugh Dunstan, Doctor Shaun Roman, Professor Rob Atkin, Doctor Clovia Holdsworth, Doctor Mark Baker, Doctor Nikki Verrills, Professor Gottfried Otting, Associate Professor Brett Nixon, Doctor Xiaojing Zhou, Ms Megan Chircop, Doctor Warwick Belcher
SchemeEquipment Grant
RoleInvestigator
Funding Start2010
Funding Finish2010
GNoG1000873
Type Of FundingInternal
CategoryINTE
UONY

ABI 7500 Real Time PCR System $34,000

Funding body: NHMRC (National Health & Medical Research Council)

Epigenetic methylation of PP2A subunit promoters in breast cancer$25,000

Funding body: Hunter Children`s Research Foundation

Funding bodyHunter Children`s Research Foundation
Project TeamDoctor Nikki Verrills, Doctor Martin Horan
SchemeResearch Grant
RoleLead
Funding Start2010
Funding Finish2010
GNoG0900148
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

20094 grants / $1,161,000

Tetraspanin proteins in prostate cancer progression and prognosis$341,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamEmeritus Professor Leonie Ashman, Doctor Nikki Verrills, Conjoint Professor Jim Denham
SchemeResearch Grant
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0188877
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Confocal Laser Scanning Microscopy for Live Cell Imaging$275,000

Funding body: ARC (Australian Research Council)

Funding bodyARC (Australian Research Council)
Project TeamConjoint Professor Keith Jones, Professor Eileen McLaughlin, Laureate Professor John Aitken, Conjoint Professor Ray Rose, Emeritus Professor John Patrick, Conjoint Professor Christina Offler, Associate Professor David McCurdy, Emeritus Professor Leonie Ashman, Professor Gordon Burns, Professor Dirk Van Helden, Doctor Nikki Verrills, Associate Professor Brett Nixon, Doctor Shaun Roman, Associate Professor Yong-Ling Ruan, Doctor Rick Thorne, Professor Mike Calford
SchemeLinkage Infrastructure Equipment & Facilities (LIEF)
RoleInvestigator
Funding Start2009
Funding Finish2009
GNoG0189038
Type Of FundingScheme excluded from IGS
CategoryEXCL
UONY

20085 grants / $1,646,290

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamConjoint Professor Stephen Ackland, Emeritus Professor Leonie Ashman, Professor John Forbes, Conjoint Professor Jim Denham, Conjoint Professor Peter Hersey, Professor Gordon Burns, Professor Adam McCluskey, Doctor Nikki Verrills
SchemeNSW MRSP Infrastructure Grant
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188622
Type Of FundingOther Public Sector - State
Category2OPS
UONY

PP2A: a novel target for leukaemia therapy$300,000

Funding body: Cancer Council NSW

Funding bodyCancer Council NSW
Project TeamDoctor Nikki Verrills, Emeritus Professor Leonie Ashman, Professor Alistair Sim, Associate Professor Danilo Perrotti, Assoc. Prof Timothy Hughes, Dr David Thomas
SchemeResearch Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0187694
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Functional investigations of novel SET splice isoforms in acute myeloid leukaemia and their potential as a therapeutic target.$270,000

Funding body: Anthony Rothe Memorial Trust

Funding bodyAnthony Rothe Memorial Trust
Project TeamDoctor Nikki Verrills
SchemeResearch Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188185
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

Novel Alternative Splice Isoforms of the SET Oncogene in Acute Myeloid Leukaemia $25,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills
SchemeProject Grant
RoleLead
Funding Start2008
Funding Finish2008
GNoG0188462
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

PP2A: A new target for asthma therapy$20,000

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamProfessor Alistair Sim, Doctor Nikki Verrills, Professor John Scott, Conjoint Professor Peter Wark
SchemeNear Miss Grant
RoleInvestigator
Funding Start2008
Funding Finish2008
GNoG0188395
Type Of FundingInternal
CategoryINTE
UONY

20077 grants / $528,630

FACSAria - Fluorescence activated cell sorter$300,000

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeResearch Infrastructure Grants
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187666
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

The role of protein phosphatase 2A in breast cancer$75,000

Funding body: Cure Cancer Australia Foundation

Funding bodyCure Cancer Australia Foundation
Project TeamDoctor Nikki Verrills
SchemeResearch Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0186797
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

HMRI Contribution toward FACSAria - Fluorescence activated cell sorter$52,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Emeritus Professor Leonie Ashman, Laureate Professor John Aitken, Professor Eileen McLaughlin, Professor Alistair Sim, Doctor Rick Thorne, Doctor Jennette Sakoff
SchemeEquipment Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0188207
Type Of FundingOther Public Sector - State
Category2OPS
UONY

Differential regulation of human mast cell degranulation by discrete forms of protein phosphatase 2A$50,000

Funding body: Asthma Foundation of New South Wales

Funding bodyAsthma Foundation of New South Wales
Project TeamProfessor Alistair Sim, Doctor Nikki Verrills, Laureate Professor Paul Foster, Conjoint Professor Peter Wark, Conjoint Professor Peter Gibson, Dr Gregory Kranias
SchemeResearch Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0187247
Type Of FundingDonation - Aust Non Government
Category3AFD
UONY

The tumour suppressor gene, PP2A, in breast cancer and its potential as a new target for therapy$29,930

Funding body: Ramaciotti Foundations

Funding bodyRamaciotti Foundations
Project TeamDoctor Nikki Verrills
SchemeResearch Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0188055
Type Of FundingGrant - Aust Non Government
Category3AFG
UONY

Polymerase Chain Reaction (PCR) machine and Spectrophotometer$20,000

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamEmeritus Professor Leonie Ashman, Professor Alistair Sim, Doctor Nikki Verrills
SchemeEquipment Grant
RoleInvestigator
Funding Start2007
Funding Finish2007
GNoG0188195
Type Of FundingOther Public Sector - Commonwealth
Category2OPC
UONY

American Association of Cancer Research, LA Convention Centre, Los Angeles, USA, 14/4/2007 - 18/4/2007$1,700

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills
SchemeTravel Grant
RoleLead
Funding Start2007
Funding Finish2007
GNoG0187550
Type Of FundingInternal
CategoryINTE
UONY

20066 grants / $505,157

The role of protein phosphates in regulating the cytoskeletal dynamics of cancer cells$292,062

Funding body: NHMRC (National Health & Medical Research Council)

Funding bodyNHMRC (National Health & Medical Research Council)
Project TeamDoctor Nikki Verrills
SchemeTraining (Postdoctoral) Fellowships - Peter Doherty Biomedical Fellowship (Australia)
RoleLead
Funding Start2006
Funding Finish2006
GNoG0185634
Type Of FundingAust Competitive - Commonwealth
Category1CS
UONY

Live cell imaging facility$149,100

Funding body: Cancer Institute NSW

Funding bodyCancer Institute NSW
Project TeamDoctor Rick Thorne, Doctor Nikki Verrills, Professor Alistair Sim, Professor Gordon Burns
SchemeResearch Infrastructure Grants
RoleInvestigator
Funding Start2006
Funding Finish2006
GNoG0186146
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

Investigating the functional role of altered expression and point mutations in the tumour suppressor gene PP2A$50,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills
SchemeSpecial Competitive Research Fund for Early Career Researchers in Cancer
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186082
Type Of FundingNot Known
CategoryUNKN
UONY

Novel protein phosphatase interactions in cancer$10,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Nikki Verrills, Professor Alistair Sim
SchemeProject Grant
RoleLead
Funding Start2006
Funding Finish2006
GNoG0186480
Type Of FundingContract - Aust Non Government
Category3AFC
UONY

High speed computer for a live cell imaging system$3,000

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamDoctor Rick Thorne, Professor Gordon Burns, Doctor Nikki Verrills, Professor Alistair Sim
SchemeEquipment Grant
RoleInvestigator
Funding Start2006
Funding Finish2006
GNoG0187279
Type Of FundingNot Known
CategoryUNKN
UONY

BioRad Mini-PROTEAN3 Electrophoresis system$995

Funding body: Hunter Medical Research Institute

Funding bodyHunter Medical Research Institute
Project TeamEmeritus Professor Leonie Ashman, Associate Professor Phillip Dickson, Emeritus Professor Peter Dunkley, Emeritus Professor John Rostas, Professor Judith Scott, Professor Alistair Sim, Doctor Nikki Verrills
SchemeEquipment Grant
RoleInvestigator
Funding Start2006
Funding Finish2006
GNoG0187280
Type Of FundingNot Known
CategoryUNKN
UONY

20051 grants / $2,430

Europhosphatases Conference 2005, 10-14 July 2005$2,430

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills
SchemeTravel Grant
RoleLead
Funding Start2005
Funding Finish2005
GNoG0185546
Type Of FundingInternal
CategoryINTE
UONY

20041 grants / $2,400

12th International Conference on Second Messenger and Phosphoproteins, 3-7 August 2004$2,400

Funding body: University of Newcastle

Funding bodyUniversity of Newcastle
Project TeamDoctor Nikki Verrills
SchemeTravel Grant
RoleLead
Funding Start2004
Funding Finish2004
GNoG0184543
Type Of FundingInternal
CategoryINTE
UONY
Edit

Research Supervision

Current Supervision

CommencedResearch Title / Program / Supervisor Type
2015Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2015Identifying the Functional Role of SBDS Protein, A Novel Drug Target in Acute Myeloid Leukaemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2015PPP2R2A - A Novel Biomarker and Therapeutic Target for Luminal B Breast Cancer
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2014To Be Advised
Human Biology, Faculty of Health and Medicine
Co-Supervisor
2007The role of protein phosphatases in breast cancer
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor
2006Role of PP2A in cancer
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor
2006PP2A in mast cell function
Biochemistry & Cell Biology, University of Newcastle
Co-Supervisor

Past Supervision

YearResearch Title / Program / Supervisor Type
2014Targeting PP2A Activation as a Novel Therapeutic Strategy for Receptor Tyrosine Kinase Driven Leukemia
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2012The Role of Protein Phosphatase 2A as a Tumour Suppressor in Breast Cancer
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2011Regulation of Mast Cell Degranulation by Protein Phosphatase 2A
Medical Science, Faculty of Health and Medicine
Principal Supervisor
2010Regulation of the Tumour Suppressor PP2A by Oncogenic Tyrosine Kinases
Medical Science, Faculty of Health and Medicine
Principal Supervisor
Edit

News

Xu Dong Zhang

$1m for visionary cancer researchers

May 1, 2015

Two of the University of Newcastle's leading researchers have been awarded more than $1m in grants to focus on discovering new methods of curbing and treating cancer.

Cancer Council NSW research grant success

$1 million in Cancer Council NSW project grants

January 12, 2015

Two University of Newcastle (UON) cancer researchers from the School of Biomedical Sciences and Pharmacy in the Faculty of Health and Medicine have been awarded more than $1 million in Cancer Council NSW project grants for 2015.

Dr Nikki Verrills

Position

Senior Lecturer
School of Biomedical Sciences and Pharmacy
Faculty of Health and Medicine

Focus area

Medical Biochemistry

Contact Details

Emailnikki.verrills@newcastle.edu.au
Phone(02) 4921 5619
Fax(02) 4921 6903

Office

RoomLS3-46
BuildingLife Sciences
LocationCallaghan
University Drive
Callaghan, NSW 2308
Australia
Edit